What are the indications, dosing regimens (including renal impairment adjustments), and contraindications for aztreonam in adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Aztreonam: Indications, Dosing, and Contraindications

Indications

Aztreonam is indicated for serious infections caused by aerobic Gram-negative bacteria, including urinary tract infections, lower respiratory tract infections (including hospital-acquired and ventilator-associated pneumonia), intra-abdominal infections, septicemia, gynecologic infections (endometritis, pelvic cellulitis), and skin/skin structure infections. 1

The drug has particular utility in three clinical scenarios:

  • Patients with β-lactam allergies: Aztreonam has minimal cross-reactivity with penicillins and cephalosporins 2
  • Combination therapy for metallo-β-lactamase (MBL)-producing organisms: When combined with ceftazidime-avibactam, aztreonam demonstrates significant activity against MBL-producing carbapenem-resistant Enterobacterales (CRE), particularly NDM and VIM producers 3
  • Empiric coverage in hospital-acquired/ventilator-associated pneumonia: Aztreonam serves as an alternative antipseudomonal agent when other β-lactams are contraindicated 4

For empiric VAP/HAP therapy in units with high rates of multidrug-resistant pathogens, aztreonam (2 g IV q8h) can be used as the antipseudomonal β-lactam component, though it must be combined with MRSA coverage and typically a second antipseudomonal agent (fluoroquinolone, aminoglycoside, or polymyxin) 4.

Dosing Regimens

Adults with Normal Renal Function

The standard dosing is severity-dependent and should be administered intravenously for serious infections 1:

  • Urinary tract infections: 500 mg to 1 g IV q8-12h
  • Moderately severe systemic infections: 1-2 g IV q8-12h
  • Severe/life-threatening infections: 2 g IV q6-8h
  • Pseudomonas aeruginosa infections: 2 g IV q6-8h (at least initially)

Maximum daily dose: 8 g/day 1

Critical administration note: Extended infusions (3 hours) are associated with improved survival in serious infections and should be considered for optimal pharmacokinetic/pharmacodynamic target attainment 3.

Pediatric Patients (≥1 month to 12 years)

Administer intravenously only 1:

  • Mild to moderate infections: 30 mg/kg IV q8h
  • Moderate to severe infections: 30 mg/kg IV q6-8h
  • Maximum daily dose: 120 mg/kg/day

There is insufficient data for intramuscular administration or dosing in pediatric patients with renal impairment 1.

Renal Impairment Adjustments (Adults)

Dosing must be adjusted based on creatinine clearance (CrCl) 1:

CrCl 10-30 mL/min/1.73 m²:

  • Give standard loading dose (1-2 g)
  • Reduce maintenance dose by 50% at usual intervals (q6-12h)

CrCl <10 mL/min/1.73 m² (including hemodialysis):

  • Give standard loading dose (500 mg, 1 g, or 2 g)
  • Maintenance: 25% of usual dose at usual intervals
  • Post-hemodialysis supplementation: Give 1/8 of initial dose after each dialysis session

The Cockcroft-Gault equation should be used to estimate CrCl when only serum creatinine is available 1.

Elderly Patients

Renal function assessment is mandatory; serum creatinine alone is unreliable 1. Calculate CrCl and adjust dosing according to renal impairment guidelines above.

Combination Therapy Considerations

For MBL-Producing CRE

Aztreonam combined with ceftazidime-avibactam is the preferred regimen for MBL-producing CRE bacteremia, showing significantly lower 30-day mortality (HR 0.37,95% CI 0.13-0.74) compared to other covering therapies 3. This combination exploits the fact that avibactam protects aztreonam from serine β-lactamases while aztreonam remains stable against MBLs.

For Mixed Infections

Aztreonam lacks activity against Gram-positive organisms and anaerobes; combination therapy is mandatory for polymicrobial infections 2, 5. Compatible combinations include:

  • Clindamycin, gentamicin, tobramycin, or cefazolin (stable 48 hours at room temperature, 7 days refrigerated) 1
  • Vancomycin or linezolid for MRSA coverage in HAP/VAP 4

Incompatible combinations: Nafcillin, cephradine, and metronidazole 1

Contraindications and Precautions

The only absolute contraindication is known hypersensitivity to aztreonam 1.

Key precautions:

  • Minimal cross-reactivity with other β-lactams, making it safe for most penicillin-allergic patients 2
  • Seizure risk with imipenem is not a concern with aztreonam (unlike carbapenems) 5
  • Not nephrotoxic and does not affect coagulation 5
  • Monitor renal function in elderly patients and adjust doses accordingly 1

Pharmacokinetic Considerations

Aztreonam achieves therapeutic concentrations in most body fluids and tissues, including bile, pleural fluid, synovial fluid, and inflamed meninges 1. The serum half-life is approximately 1.7 hours in patients with normal renal function, increasing to 6-8 hours in severe renal impairment 1, 6. Approximately 60-70% is excreted unchanged in urine by 8 hours 1.

For optimal PK/PD target attainment (60% fT>MIC), extended infusions over 2-3 hours are preferred for serious infections, particularly in patients with preserved renal function (CrCl >50 mL/min) 3, 7.

References

2
Research

Aztreonam activity, pharmacology, and clinical uses.

The American journal of medicine, 1990

Related Questions

When should aztreonam be preferred?
What are the indications, dosing regimens, and treatment duration for aztreonam in adult patients with normal, moderately impaired, and severely impaired renal function?
What is the recommended aztreonam dosing and treatment plan for a patient with a lower respiratory tract infection and chronic kidney disease, adjusted for renal function?
What is the appropriate aztreonam dosing for an adult patient with renal impairment?
What is the recommended dose of aztreonam (Aztreonam) for a patient with urosepsis and impaired renal function (creatinine clearance (CrCl) of 46)?
How should metformin dosing be adjusted according to estimated glomerular filtration rate and when should it be discontinued in renal impairment?
What renal dose adjustment is recommended for linagliptin in patients with impaired renal function?
In a patient with clear‑cell renal carcinoma, do adrenal lesions seen on PET represent metastases, and what is the recommended diagnostic and treatment approach?
How do I initiate levothyroxine therapy, including starting dose and administration guidelines?
What is the appropriate management of sick euthyroid syndrome?
What is the appropriate management for a calcified hepatic hydatid cyst in an asymptomatic patient?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.